secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001628280-22-027930
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q3 net revenue $55.8M (incl. $30M milestone); lowers FY22 product revenue guidance to $100-105M
--------------------------------------------------------------------------------

- Net loss narrowed to $9.0M ($0.06/sh) from $50.3M loss ($0.39/sh) in Q3 2021.
- LUPKYNIS net product revenue $25.5M; 2022 product revenue guidance cut to $100-105M from unstated prior range.
- Patients on therapy grew to ~1,354 (up from 1,274 at Q2 2022); PSFs added 374 vs 412 Y/Y.
- EC granted marketing authorization for LUPKYNIS in Europe; $30M milestone from Otsuka recognized and received.
- Cash at $376.6M (Sep 30) and ~$400M (Oct 31); IPR decision on LUPKYNIS patent expected by July 26, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022027930/0001628280-22-027930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022027930/auph-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-027930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer